课题基金 / 基金详情

PREVENTION OF GRAFT-VERSUS-HOST DISEASE BY TARGETING ANTIGEN-PRESENTING CELLS AND BY TOLERANCE INDUCTION

PREVENTION OF GRAFT-VERSUS-HOST DISEASE BY TARGETING ANTIGEN-PRESENTING CELLS AND BY TOLERANCE INDUCTION
通过靶向抗原呈递细胞和耐受诱导来预防移植物抗宿主病
批准号:
15591007
负责人:
TESHIMA Takanori
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

TESHIMA Takanori的其他基金

相似基金

相关文献

中文摘要
翻译
我们首先研究在GVHD小鼠模型中确定最关键的抗原提呈细胞(APC)。我们发现,仅宿主来源的树突状细胞(DC)就足以引起移植物抗宿主病(GVHD),而不是供者。相反,宿主来源的B细胞在体内不能诱导移植物抗宿主病。这些结果表明,选择性地消除或抑制宿主APC可能是抑制GVHD诱导的一种有前途的策略。我们还测试了几种诱导耐受的免疫学方法是否可以用来再次抑制GVHD小鼠模型的GVHD。我们研究了宿主NKT细胞的刺激是否可以调节小鼠的急性移植物抗宿主病(GVHD)。在异基因骨髓移植后第0天向受体小鼠注射合成的NKT细胞配体α-半乳糖神经酰胺(α-GalCer),可促进供体T细胞的Th2型极化,并显著降低GVHD的关键介质肿瘤坏死因子-α。给受体小鼠一次注射α-GalCer可显著降低移植物抗宿主病的发病率和死亡率。然而,同样的处理不能在NKT细胞缺陷的CD1d基因敲除(CD1d;-/->)或IL-4;-/->受体小鼠或以STAT6;-/->小鼠为供体时提供对移植物抗宿主病的保护作用,表明宿主NKT细胞、宿主产生IL-4以及供体T细胞介导的Th2细胞因子应答在α-GalCer对移植物抗宿主病的保护作用中起关键作用。因此,通过给予NKT配体刺激宿主NKT细胞可以通过STAT6依赖的机制诱导供体T细胞Th2极化来调节急性GVHD,可能是预防GVHD的一种新策略。
英文摘要
We first studied to determine the most critical antigen-presenting cells(APCs) in mouse models of GVHD. We found that hostr, but not donor, derived dendritic cells(DCs) alone are sufficient to cause GVHD. In contrast, host-derived B cells atone were not able to induce GVHD in vivo. These results suggest that selective elimination or suppression of host APCs can be a promising strategy to inhibit the induction of GVHD. We also tested whether several irnmunological approaches to induce tolerance can be applied to suppress GVHD again in mouse models of GVHD. We have investigated whether stimulation of host NKT cells could modulate acute graft-versus-host disease(GVHD) in mice. Injection of the synthetic NKT cell ligandα-galactosylceramide(α-GalCer) to recipient mice on day 0 following allogeneic bone marrow transplantation promoted Th2 polarization of donor T cells and a dramatic reduction of serum TNF-a, a critical mediator of GVHD. A single injection of α-GalCer to recipient mice significantly reduced morbidity and mortality of GVHD. However, the same treatment was unable to confer protection against GVHD in NKT cell deficient CD1d knockout (CD1d^<-/->) or IL-4^<-/-> recipient mice or when STAT6^<-/-> mice were used as donors, indicating the critical role of host NKT cells, host production of IL-4,and Th2 cytokine responses mediated by donor T cells on the protective effects of α-GalCer against GVHD. Thus stimulation of host NKT cells through administration of NKT ligand can regulate acute GVHD by inducing Th2 polarization of donor T cells via STAT6-dependent mechanisms and might represent a novel strategy for prevention of GVHD.
期刊论文(38)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/s0301-472x(03)00198-x
发表时间: 2003-10-01
期刊: EXPERIMENTAL HEMATOLOGY
影响因子: 2.6
作者: [Duffner, U, Lu, B, Ferrara, JLM]
通讯作者: Ferrara, JLM
DOI: 10.1182/blood-2004-08-3036
发表时间: 2005-03-01
期刊: BLOOD
影响因子: 20.3
作者: [Maeda, Y, Levy, RB, Ferrara, JLM]
通讯作者: Ferrara, JLM
Pathogenesis of acute and chronic graft-versus-host disease.
急性和慢性移植物抗宿主病的发病机制。
DOI: --
发表时间: 2004
期刊: Clinical Bone Marrow and Blood Stem Cell Transplantation 3rd Edition(Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, Brenner M(ed))(Cambridge University Press, Cambridge, United Kingdom)
影响因子: --
作者: [Teshima T, Ferrara JLM]
通讯作者: Ferrara JLM
Clouthier SG, Cooke KR, Teshima T, Lowler KP, Liu C, Connolly K, Ferrara JLM: "Repifermin (Keratinocyte Growth Factor-2), reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect"Biol Blood Marrow Transplant. 9. 59
Clouthier SG、Cooke KR、Teshima T、Lowler KP、Liu C、Connolly K、Ferrara JLM:“Repifermin(角质细胞生长因子-2)可降低移植物抗宿主病的严重程度,同时保留移植物抗白血病效应
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 13 条
    Crosstalk between graft-versus-host disease and infection following allogeneic hematopoietic stem cell transplantation
    Novel mechanisms of alloreactive T-cell activation in GVHD and GVL
    Comprehensive analysis of role of dendritic cells and target cells in graft-versus-host disease and graft-versus-leukemia
    • 批准号:
      17390280
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.52万
    • 财政年份:
      2005
    • 负责人:
      TESHIMA Takanori
    • 依托单位:
    国内基金
    海外基金
    α-galactosylceramide增强SOCS1基因沉默AAV2/IL-12DC诱导的特异性CTL过继治疗肺癌的动物实验研究
    • 批准号:
      81372454
    • 项目类别:
      面上项目
    • 资助金额:
      16.0万元
    • 批准年份:
      2013
    • 负责人:
      钱高潮
    • 依托单位: